Asset Details
Do you wish to reserve the book?
A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway
Do you wish to request the book?
A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
A small molecule G6PD inhibitor reveals immune dependence on pentose phosphate pathway
2020
Overview
Glucose is catabolized by two fundamental pathways, glycolysis to make ATP and the oxidative pentose phosphate pathway to make reduced nicotinamide adenine dinucleotide phosphate (NADPH). The first step of the oxidative pentose phosphate pathway is catalyzed by the enzyme glucose-6-phosphate dehydrogenase (G6PD). Here we develop metabolite reporter and deuterium tracer assays to monitor cellular G6PD activity. Using these, we show that the most widely cited G6PD antagonist, dehydroepiandosterone, does not robustly inhibit G6PD in cells. We then identify a small molecule (G6PDi-1) that more effectively inhibits G6PD. Across a range of cultured cells, G6PDi-1 depletes NADPH most strongly in lymphocytes. In T cells but not macrophages, G6PDi-1 markedly decreases inflammatory cytokine production. In neutrophils, it suppresses respiratory burst. Thus, we provide a cell-active small molecule tool for oxidative pentose phosphate pathway inhibition, and use it to identify G6PD as a pharmacological target for modulating immune response.
Identification of an improved glucose-6-phosphate dehydrogenase (G6PD) inhibitor G6PDi-1 blocks G6PD activity more robustly than the widely cited antagonist DHEA. G6PDi-1 treatment blocks T cell cytokine production and neutrophil oxidative burst.
Publisher
Nature Publishing Group US,Nature Publishing Group
Subject
/ Adenine
/ Animals
/ Chemistry and Materials Science
/ Dehydroepiandrosterone - pharmacology
/ Dose-Response Relationship, Drug
/ Enzyme Inhibitors - pharmacology
/ Glucose
/ Glucose 6 phosphate dehydrogenase
/ Glucosephosphate dehydrogenase
/ Glucosephosphate Dehydrogenase - antagonists & inhibitors
/ Glucosephosphate Dehydrogenase - immunology
/ Glucosephosphate Dehydrogenase - metabolism
/ Humans
/ Lymphocyte Activation - drug effects
/ Macrophage Activation - drug effects
/ NADP
/ NADP - antagonists & inhibitors
/ Nicotinamide adenine dinucleotide
/ Pentose
/ Pentose Phosphate Pathway - drug effects
